Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maha Hussain

Showing results (141-150 of 213) with videos related to

Pageof 22
Sort By:
European Urology|April 21, 2023
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without OrteronelPrimo N Lara, Edward Mayerson, Erik Gertz, et al.
JAMA Network Open|July 9, 2024
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 TrialGeorges Gebrael, Yeonjung Jo, Umang Swami, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2022
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPERAnthony M Joshua, Andrew Armstrong, Megan Crumbaker, et al.
European Urology Oncology|August 19, 2020
Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED TrialAlan H Bryce, Yu Hui Chen, Glenn Liu, et al.
Bladder Cancer (Amsterdam, Netherlands)|February 13, 2018
Molecular Correlates of <i>In Vitro</i> Responses to Dacomitinib and Afatinib in Bladder CancerShuzo Tamura, Yin Wang, Brendan Veeneman, et al.
Urology|December 29, 2020
Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting SummaryMartin R Hofmann, Maha Hussain, Scott M Dehm, et al.
Infant Mental Health Journal|November 4, 2025
Development of a revised and abbreviated version of the postpartum bonding questionnaire (PBQ-R): First U.S. validation and association to child outcomesAndréane Lavallée, Jennifer M Warmingham, Mark A Reimers, et al.
The Lancet. Oncology|February 14, 2022
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trialAntoine Thiery-Vuillemin, Johann de Bono, Maha Hussain, et al.
European Urology Oncology|April 17, 2025
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trialDaniel Sentana-Lledo, Xiangying Chu, Charles J Ryan, et al.
Clinical Genitourinary Cancer|February 14, 2009
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical researchMichael J Morris, Ethan M Basch, George Wilding, et al.
Pageof 22

Showing results (141-150 of 213) with videos related to

Sort By:
Pageof 22
European Urology|April 21, 2023
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without OrteronelPrimo N Lara, Edward Mayerson, Erik Gertz, et al.
JAMA Network Open|July 9, 2024
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 TrialGeorges Gebrael, Yeonjung Jo, Umang Swami, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2022
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPERAnthony M Joshua, Andrew Armstrong, Megan Crumbaker, et al.
European Urology Oncology|August 19, 2020
Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED TrialAlan H Bryce, Yu Hui Chen, Glenn Liu, et al.
Bladder Cancer (Amsterdam, Netherlands)|February 13, 2018
Molecular Correlates of <i>In Vitro</i> Responses to Dacomitinib and Afatinib in Bladder CancerShuzo Tamura, Yin Wang, Brendan Veeneman, et al.
Urology|December 29, 2020
Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting SummaryMartin R Hofmann, Maha Hussain, Scott M Dehm, et al.
Infant Mental Health Journal|November 4, 2025
Development of a revised and abbreviated version of the postpartum bonding questionnaire (PBQ-R): First U.S. validation and association to child outcomesAndréane Lavallée, Jennifer M Warmingham, Mark A Reimers, et al.
The Lancet. Oncology|February 14, 2022
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trialAntoine Thiery-Vuillemin, Johann de Bono, Maha Hussain, et al.
European Urology Oncology|April 17, 2025
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trialDaniel Sentana-Lledo, Xiangying Chu, Charles J Ryan, et al.
Clinical Genitourinary Cancer|February 14, 2009
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical researchMichael J Morris, Ethan M Basch, George Wilding, et al.
Pageof 22